Prous Science
Prous Science was an international health science publishing company, established in 1965 and headquartered in Barcelona, Spain. The company was acquired by Thomson Reuters in 2007.[1]
The Prous Institute for Biomedical Research
Judicial news: Prous Institute for Biomedical Research
News Tribunales Cronica Global 5 /3/2016
News Tribunales El Mundo 14 /03/2016 /Prous Institute investigada
http://www.elmundo.es/cataluna/2016/03/14/56e5a7d3268e3ee2638b4630.html
News Tribunales Ok diario 28 /03/2016
was founded in 2000 by Dr Josep Prous Jr as a spinoff biotech company of Prous Science.[2] Dr. J.R. Prous was the CEO and president of Prous Science.[1] Its head offices are located in Barcelona and it has subsidiaries in Philadelphia (United States), Buenos Aires (Argentina) and Tokyo (Japan). Its research is based on the use of datamining, statistical analysis and chemoinformatic techniques, a recent and innovative international concept registered under the name "druginformatics". These techniques are complemented by laboratory methods from combinatorial chemistry, molecular biology and functional genomics.
Science
The 'Prous Scientific Integrity' data portal was launched in 2001.[3] In 2008, Prous pharmacology and drug discovery content was made available through Thomson Reuters services.[4]
The Prous Institute for Biomedical Research launched its Symmetry Module (SM), an in silico solution for drug discovery and toxicity screening.[5]
References
- 1 2 "Mission and History". ProusResearch.com. Retrieved 24 May 2014.
- ↑ "Corporate Key Facts". ProusResearch.com. Retrieved 24 May 2014.
- ↑ "Prous Science Launches Integrity(R), the World's First Integrated Drug Discovery Portal". PRNewswire.com. 25 Jun 2001. Retrieved 21 May 2014.
- ↑ "Thomson Reuters Launches New Predictive Pharmacology Module As Part Of Its Prous Science Integrity Platform". Thomsonreuters.com. 28 Aug 2008. Retrieved 21 May 2014.
- ↑ "A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities". Toxicol Appl Pharmacol 273 (3): 427–34. 15 Dec 2013. doi:10.1016/j.taap.2013.09.015.